Ranked API manufacturers
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 2011. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 10 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
10 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 2000. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 8 markets.
Last FDA inspection
2024 · VAI
GMP recognised in
8 markets
03 Switzerland
Makes the API
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 1998. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Last FDA inspection
2024 · VAI
GMP recognised in
2 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs for leuprolide, filing since 1998. Its 2025 FDA inspection closed as VAI.
Last FDA inspection
2025 · VAI
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
18 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs for leuprolide, filing since 2012. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Last FDA inspection
2023 · VAI
GMP recognised in
1 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 2016. Its 2024 FDA inspection closed as NAI.
Last FDA inspection
2024 · NAI
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 2012. Its 2022 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Last FDA inspection
2022 · NAI
GMP recognised in
1 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 2020. Its 2023 FDA inspection closed as VAI.
Last FDA inspection
2023 · VAI
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 2017. Its 2025 FDA inspection closed as VAI.
Last FDA inspection
2025 · VAI
GMP recognised in
Not established
Holds one active US DMF for leuprolide, filing since 2020.
Last FDA inspection
Not established
GMP recognised in
Not established
12 South Korea
Makes the API
Credentials confirmed against the regulator files on 25 July 2026
Last FDA inspection
Not established
GMP recognised in
Not established
13 Netherlands
Makes the API
Credentials confirmed against the regulator files on 25 July 2026
Last FDA inspection
Not established
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 2019.
Last FDA inspection
Not established
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for leuprolide, filing since 2024.
Last FDA inspection
Not established
GMP recognised in
Not established
Registered with SFDA (Saudi Arabia) for leuprolide. Its GMP is recognised in 12 markets.
Last FDA inspection
Not established
GMP recognised in
12 markets
How this listing is sourced Regulator filings, warehouse snapshot 9 July 2026
View profile 13 more manufacturers hold filings for leuprolide
The names are listed below. The filings, inspection history and GMP certificates behind
each one are available with a free account.
Open the full list with a free account Contract manufacturers (6)
Contract manufacturers make to order rather than holding their own filing for this
molecule.
Finished-dose makers (27)
How this list is built
The order is set by active filings weighted by regulator, inspection outcomes and their
recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags.
Every factor appears on the card it produced.
Read the full method.
- Active US DMFs
- FDA, List of Drug Master Files
- Valid CEPs
- EDQM certificate database
- Inspection outcomes
- FDA inspection classifications
- GMP certificates
- EudraGMDP and national regulators